Back to News
Market Impact: 0.3
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights
Source: PR Newswire
Legal & LitigationHealthcare & Biotech
DJS Law Group reminded investors of a securities class-action lawsuit against Capricor Therapeutics (NASDAQ: CAPR), alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act and SEC Rule 10b-5. The notice signals potential litigation, disclosure, and reputational risks for the biotechnology company, though the excerpt provides no alleged damages, class period, or operational impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately negative
Sentiment Score
-0.45
Ticker Sentiment
CAPR-0.85
More News
- J&J's potential 'game-changer' drug — plus, what Microsoft's mass buyouts mean
- ‘Imposed significant financial harm’: 20 states join the FTC in suing Dollar General for ‘deceptive pricing practices’ despite ‘corporate knowledge’
- The excitement around Moderna’s cancer vaccine is cooling. Here’s why.
- Anthropic’s dual-class share structure borrows ideas from Mark Zuckerberg, Elon Musk—and the New York Times
- Cramer: I asked some tech insiders what to buy. They surprisingly said this drug stock
- Moderna CEO Sees Cancer Vaccines Working Beyond Melanoma